Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer - PubMed (original) (raw)
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
Christoph A Klein et al. Lancet. 2002.
Abstract
Background: Because cancer patients with small tumours often relapse despite local and systemic treatment, we investigated the genetic variation of the precursors of distant metastasis at the stage of minimal residual disease. Disseminated tumour cells can be detected by epithelial markers in mesenchymal tissues and represent targets for adjuvant therapies.
Methods: We screened 525 bone-marrow, blood, and lymph-node samples from 474 patients with breast, prostate, and gastrointestinal cancers for single disseminated cancer cells by immunocytochemistry with epithelial-specific markers. 71 (14%) of the samples contained two or more tumour cells whose genomic organisation we studied by single cell genomic hybridisation. In addition, we tested whether TP53 was mutated. Hierarchical clustering algorithms were used to determine the degree of clonal relatedness of sister cells that were isolated from individual patients.
Findings: Irrespective of cancer type, we saw an unexpectedly high genetic divergence in minimal residual cancer, particularly at the level of chromosomal imbalances. Although few disseminated cells harboured TP53 mutations at this stage of disease, we also saw microheterogeneity of the TP53 genotype. The genetic heterogeneity was strikingly reduced with the emergence of clinically evident metastasis.
Interpretation: Although the heterogeneity of primary tumours has long been known, we show here that early disseminated cancer cells are genomically very unstable as well. Selection of clonally expanding cells leading to metastasis seems to occur after dissemination has taken place. Therefore, adjuvant therapies are confronted with an extremely large reservoir of variant cells from which resistant tumour cells can be selected.
Similar articles
- Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ, Cote RJ. Diel IJ, et al. Cancer Treat Rev. 2000 Feb;26(1):53-65. doi: 10.1053/ctrv.1999.0150. Cancer Treat Rev. 2000. PMID: 10660491 Review. - Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.
Austrup F, Uciechowski P, Eder C, Böckmann B, Suchy B, Driesel G, Jäckel S, Kusiak I, Grill HJ, Giesing M. Austrup F, et al. Br J Cancer. 2000 Dec;83(12):1664-73. doi: 10.1054/bjoc.2000.1501. Br J Cancer. 2000. PMID: 11104564 Free PMC article. - Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, Pantel K, Riethmüller G. Kufer P, et al. Cancer Res. 2002 Jan 1;62(1):251-61. Cancer Res. 2002. PMID: 11782385 - Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells.
Pantel K, Otte M. Pantel K, et al. Semin Cancer Biol. 2001 Oct;11(5):327-37. doi: 10.1006/scbi.2001.0388. Semin Cancer Biol. 2001. PMID: 11562175 Review. - Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD, Taran FA, Wallwiener M, Hahn M, Becker S, Solomayer EF, Brucker SY, Fehm TN, Wallwiener D. Hartkopf AD, et al. Eur J Cancer. 2014 Oct;50(15):2550-9. doi: 10.1016/j.ejca.2014.06.025. Epub 2014 Aug 2. Eur J Cancer. 2014. PMID: 25096167
Cited by
- Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.
Al-Ruwishan A, Amer B, Salem A, Abdi A, Chimpandu N, Esa A, Melemenis A, Saleem MZ, Mathew R, Gamallat Y. Al-Ruwishan A, et al. Curr Issues Mol Biol. 2024 Aug 1;46(8):8340-8367. doi: 10.3390/cimb46080492. Curr Issues Mol Biol. 2024. PMID: 39194709 Free PMC article. Review. - Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
Gan J, Huang M, Wang W, Fu G, Hu M, Zhong H, Ye X, Cao Q. Gan J, et al. J Transl Med. 2024 May 6;22(1):428. doi: 10.1186/s12967-024-05146-2. J Transl Med. 2024. PMID: 38711158 Free PMC article. - Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells.
Rosano D, Sofyali E, Dhiman H, Ghirardi C, Ivanoiu D, Heide T, Vingiani A, Bertolotti A, Pruneri G, Canale E, Dewhurst HF, Saha D, Slaven N, Barozzi I, Li T, Zemlyanskiy G, Phillips H, James C, Győrffy B, Lynn C, Cresswell GD, Rehman F, Noberini R, Bonaldi T, Sottoriva A, Magnani L. Rosano D, et al. Cancer Discov. 2024 May 1;14(5):866-889. doi: 10.1158/2159-8290.CD-23-1161. Cancer Discov. 2024. PMID: 38527495 Free PMC article. - Unveiling the best predictive models for early‑onset metastatic cancer: Insights and innovations (Review).
Yu L, Huang Z, Xiao Z, Tang X, Zeng Z, Tang X, Ouyang W. Yu L, et al. Oncol Rep. 2024 Apr;51(4):60. doi: 10.3892/or.2024.8719. Epub 2024 Mar 8. Oncol Rep. 2024. PMID: 38456540 Free PMC article. Review. - The reckoning of chromosomal instability: past, present, future.
Lynch A, Bradford S, Burkard ME. Lynch A, et al. Chromosome Res. 2024 Feb 17;32(1):2. doi: 10.1007/s10577-024-09746-y. Chromosome Res. 2024. PMID: 38367036 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous